查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1974061

放射性药物生产市场分析及预测（至2035年）：类型、产品类型、服务、技术、应用、剂型、最终用户、製程、设备、解决方案

Radiopharmaceutical Manufacturing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Form, End User, Process, Equipment, Solutions
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5个工作天内

价格
简介目录

放射性药物生产市场预计将从2024年的55亿美元成长到2034年的130亿美元，复合年增长率约为9%。放射性药物生产市场涵盖用于医学成像和治疗的放射性化合物的生产。这些化合物在核子医学中至关重要，对包括癌症和心血管疾病在内的多种疾病的诊断和治疗起着关键作用。推动市场成长的因素包括分子成像技术的进步、慢性病发病率的上升以及对个人化医疗日益增长的需求。此外，对监管合规性和放射性药物生产製程技术创新的高度重视也进一步推动了市场成长。

放射性药物生产市场持续稳定成长，这主要得益于核医的进步和癌症发生率的上升。治疗性放射性药物领域处于领先地位，这主要得益于标靶癌症治疗的日益普及。在该领域中，β和α发射体是表现最佳的子领域，它们能够提供精准的治疗方案，且副作用极小。诊断性放射性药物领域紧随其后，其中PET和SPECT示踪剂凭藉其卓越的成像能力发挥主导作用。心血管和神经系统疾病盛行率的不断上升进一步推动了对这些诊断试剂的需求。放射性药物生产领域的新兴技术，例如自动化合成模组和迴旋加速器技术的进步，正在提高生产效率和扩充性。此外，製药公司与研究机构之间的合作正在促进创新，并加速新型放射性药物的研发。严格的法规结构和品质标准确保了这些产品的安全性和有效性，从而提升了市场信誉和医疗服务提供者的信任度。

市场区隔
种类 诊断放射性药物、治疗放射性药物、研究放射性药物
产品 Technetium-99m、碘-131、氟代脱氧葡萄糖（FDG）、镓-68、钇-90、镏-177、镭-223
服务 契约製造、品质保证、法规支援、物流和供应链管理
科技 迴旋加速器、核子反应炉、发电机、线性加速器
应用领域 肿瘤科、心臟科、神经科、内分泌科
形式 液体、固体、气体
最终用户 医院、诊断中心、学术研究机构、製药公司
流程 合成、纯化、贴标、包装
装置 PET扫描器、SPECT扫描器、伽马摄影机
解决方案 影像解决方案、治疗解决方案、放射性药物解决方案

市场概况：

放射性药物生产市场正经历动态的市场份额分布，这主要受策略定价和创新产品推出的驱动。主要企业正致力于拓展产品组合，并推出新型放射性药物，以满足日益增长的精准医疗需求。这项策略扩张得益于核医的进步和慢性病盛行率的上升。该市场的特点是竞争激烈的定价策略，力求在价格可负担性和最尖端科技之间取得平衡，从而确保更广泛的患者群体能够获得所需药物。放射性药物生产市场的竞争异常激烈，主要企业透过技术创新和策略联盟争夺主导。监管的影响至关重要，严格的指导方针塑造市场行为，并确保药物的安全性和有效性。北美和欧洲凭藉其健全的法规结构保持主导地位，而亚太地区正在崛起为一个盈利的成长区域。持续的研发正在推动诊断和治疗领域的新应用，为市场带来了光明的前景。

主要趋势和驱动因素：

放射性药物製造市场在分子成像技术和标靶治疗进步的推动下持续稳定成长。主要趋势包括PET和SPECT成像技术的日益普及，这些技术能够提高诊断准确性并提供个人化治疗方案。癌症和心血管疾病的日益普及推动了对这些技术的需求，这些技术能够实现早期检测和有效监测。监管部门的核准以及製药公司与研究机构之间的合作正在加速放射性药物的创新。新型放射性同位素和放射性标记化合物的开发正在扩大治疗范围，为市场参与者创造盈利的机会。此外，人工智慧（AI）与诊断成像系统的整合正在提高诊断能力，进一步推动市场成长。对医疗基础设施（尤其是在新兴国家）的投资不断增加，正在推动新製造设施的建设。政府旨在改善先进医疗技术可近性的措施也支持了这一趋势。预计这些因素将共同推动市场持续成长，以满足对精准高效诊断解决方案日益增长的需求。

限制与挑战：

放射性药物生产市场面临许多重大限制与挑战。监管的复杂性构成了一大障碍，放射性药物的生产和分销受到严格的监管。遵守这些法规需要投入大量的时间和资源，这可能会阻碍创新和市场准入。另一个挑战是生产所需的原材料（尤其是同位素）供应有限。这种短缺会扰乱供应链，影响生产计划，并增加成本。此外，生产设施和设备的高成本也构成了沉重的财务负担，尤其对于新参与企业。该市场也面临着对高技能专业人才的需求。由于该行业的特殊性，招募和留住熟练的专业人才至关重要，但也极具挑战性。最后，公众对放射性物质的认知和安全担忧可能会阻碍市场成长，因此需要製定强有力的教育和传播策略来建立信任。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 诊断用放射性药物
    • 治疗性放射性药物
    • 研究用放射性药物
  • 市场规模及预测：依产品划分
    • Technetium-99m
    • 碘-131
    • 氟代脱氧葡萄糖（FDG）
    • 镓-68
    • 钇-90
    • 镏-177
    • 镭-223
  • 市场规模及预测：依服务划分
    • 契约製造
    • 品质保证
    • 监管支持
    • 物流与供应链管理
  • 市场规模及预测：依技术划分
    • 迴旋加速器
    • 核子反应炉
    • 发电机
    • 直线加速器
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 心臟病学
    • 神经病学
    • 内分泌学
  • 市场规模及预测：依类型
    • 液体
    • 固体的
    • 气体
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊断中心
    • 学术研究机构
    • 製药公司
  • 市场规模及预测：依製程划分
    • 合成
    • 纯化
    • 符号
    • 包装
  • 市场规模及预测：依设备划分
    • PET扫描仪
    • SPECT扫描仪
    • 伽马摄影机
  • 市场规模及预测：按解决方案划分
    • 影像解决方案
    • 治疗方案
    • 放射性药物解决方案

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Advanced Accelerator Applications
  • Blue Earth Diagnostics
  • ITM Isotopen Technologien Munchen
  • Cyclopharm
  • NorthStar Medical Radioisotopes
  • Jubilant Radiopharma
  • Sofie Biosciences
  • Shine Medical Technologies
  • Eckert & Ziegler
  • Isotopia Molecular Imaging
  • Curium Pharma
  • Trace-Ability
  • Telix Pharmaceuticals
  • Alpha Tau Medical
  • Radiomedix

第九章：关于我们

简介目录
Product Code: GIS34194

Radiopharmaceutical Manufacturing Market is anticipated to expand from $5.5 billion in 2024 to $13 billion by 2034, growing at a CAGR of approximately 9%. The Radiopharmaceutical Manufacturing Market encompasses the production of radioactive compounds used in medical imaging and therapy. These compounds, integral to nuclear medicine, are pivotal for diagnosing and treating various conditions, including cancer and cardiovascular diseases. The market is driven by advancements in molecular imaging, increasing prevalence of chronic diseases, and rising demand for personalized medicine. Emphasis on regulatory compliance and technological innovation in radiopharmaceutical production processes further propels market growth.

The Radiopharmaceutical Manufacturing Market is experiencing robust expansion, propelled by advancements in nuclear medicine and increased incidence of cancer. The therapeutic radiopharmaceuticals segment is at the forefront, driven by the rising adoption of targeted cancer therapies. Within this segment, beta emitters and alpha emitters are top-performing sub-segments, offering precise treatment options with minimal side effects. The diagnostic radiopharmaceuticals segment follows closely, with PET tracers and SPECT tracers leading the charge due to their enhanced imaging capabilities. The growing prevalence of cardiovascular and neurological disorders further fuels demand for these diagnostic agents. Emerging technologies in radiopharmaceutical production, such as automated synthesis modules and cyclotron advancements, are boosting efficiency and scalability. Additionally, partnerships between pharmaceutical companies and research institutions are fostering innovation and accelerating the development of novel radiopharmaceuticals. Stringent regulatory frameworks and quality standards ensure the safety and efficacy of these products, enhancing market credibility and trust among healthcare providers.

Market Segmentation
TypeDiagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals, Research Radiopharmaceuticals
ProductTechnetium-99m, Iodine-131, Fluorodeoxyglucose (FDG), Gallium-68, Yttrium-90, Lutetium-177, Radium-223
ServicesContract Manufacturing, Quality Assurance, Regulatory Support, Logistics and Supply Chain Management
TechnologyCyclotron, Nuclear Reactor, Generator, Linear Accelerator
ApplicationOncology, Cardiology, Neurology, Endocrinology
FormLiquid, Solid, Gas
End UserHospitals, Diagnostic Centers, Academic and Research Institutes, Pharmaceutical Companies
ProcessSynthesis, Purification, Labeling, Packaging
EquipmentPET Scanners, SPECT Scanners, Gamma Cameras
SolutionsImaging Solutions, Therapeutic Solutions, Radiopharmacy Solutions

Market Snapshot:

The Radiopharmaceutical Manufacturing Market is witnessing a dynamic landscape with robust market share distribution influenced by strategic pricing and innovative product launches. Key industry players are focusing on expanding their portfolios, introducing new radiopharmaceuticals to meet growing demand for precision medicine. This strategic expansion is driven by advancements in nuclear medicine and the increasing prevalence of chronic diseases. The market is characterized by a competitive pricing strategy that balances affordability with cutting-edge technology, ensuring accessibility to a broader demographic. Competition within the Radiopharmaceutical Manufacturing Market is intense, with major firms vying for dominance through technological innovation and strategic partnerships. Regulatory influences play a pivotal role, with stringent guidelines shaping market practices and ensuring safety and efficacy. North America and Europe maintain leadership due to robust regulatory frameworks, while Asia-Pacific emerges as a lucrative growth region. The market's future is promising, with ongoing research and development fostering novel applications in diagnostic and therapeutic areas.

Geographical Overview:

The radiopharmaceutical manufacturing market is witnessing notable growth across various regions, each presenting unique opportunities. North America leads, driven by advanced healthcare infrastructure and increasing adoption of nuclear medicine. The presence of key industry players and a robust regulatory framework further bolster the market's expansion. Europe follows closely, with significant investments in research and development of novel radiopharmaceuticals. The region's strong focus on cancer treatment and neurological disorders enhances its market growth. In the Asia Pacific, rapid technological advancements and rising healthcare expenditure are propelling the market. Countries like China and India are emerging as lucrative growth pockets due to their large patient populations and increasing demand for diagnostic and therapeutic radiopharmaceuticals. Latin America and the Middle East & Africa are also witnessing growth, albeit at a slower pace. In Latin America, improving healthcare infrastructure and growing awareness about nuclear medicine are key drivers. Meanwhile, the Middle East & Africa are recognizing the potential of radiopharmaceuticals in addressing unmet medical needs.

Key Trends and Drivers:

The radiopharmaceutical manufacturing market is experiencing robust expansion, driven by advancements in molecular imaging and targeted therapies. A key trend is the increasing adoption of PET and SPECT imaging technologies, which offer enhanced diagnostic accuracy and personalized treatment options. The rising prevalence of cancer and cardiovascular diseases is propelling demand for these technologies, as they enable early detection and effective monitoring. Regulatory approvals and collaborations between pharmaceutical companies and research institutions are accelerating innovation in radiopharmaceuticals. The development of novel radioisotopes and radiolabeled compounds is expanding the therapeutic scope, creating lucrative opportunities for market players. Additionally, the integration of artificial intelligence in imaging systems is enhancing diagnostic capabilities, further boosting market growth. Growing investments in healthcare infrastructure, particularly in emerging economies, are facilitating the establishment of new manufacturing facilities. This trend is supported by government initiatives aimed at improving access to advanced medical technologies. The market is poised for sustained growth as these factors converge to meet the increasing demand for precise and effective diagnostic solutions.

Restraints and Challenges:

The Radiopharmaceutical Manufacturing Market encounters several significant restraints and challenges. Regulatory complexities present a formidable barrier, as stringent guidelines govern the production and distribution of radiopharmaceuticals. Compliance with these regulations demands substantial investment in time and resources, potentially stifling innovation and market entry. Another challenge is the limited availability of raw materials, particularly isotopes, which are critical for manufacturing. This scarcity can lead to supply chain disruptions, affecting production schedules and increasing costs. Furthermore, the high cost of production facilities and equipment poses a significant financial burden, especially for new entrants. The market also grapples with the need for highly specialized workforce. The recruitment and retention of skilled professionals are essential, yet challenging, due to the niche nature of the industry. Lastly, public perception and safety concerns about radioactive materials can hinder market growth, necessitating robust education and communication strategies to build trust.

Key Players:

Advanced Accelerator Applications, Blue Earth Diagnostics, ITM Isotopen Technologien M\unchen, Cyclopharm, NorthStar Medical Radioisotopes, Jubilant Radiopharma, Sofie Biosciences, Shine Medical Technologies, Eckert & Ziegler, Isotopia Molecular Imaging, Curium Pharma, Trace-Ability, Telix Pharmaceuticals, Alpha Tau Medical, Radiomedix

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Equipment
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Diagnostic Radiopharmaceuticals
    • 4.1.2 Therapeutic Radiopharmaceuticals
    • 4.1.3 Research Radiopharmaceuticals
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Technetium-99m
    • 4.2.2 Iodine-131
    • 4.2.3 Fluorodeoxyglucose (FDG)
    • 4.2.4 Gallium-68
    • 4.2.5 Yttrium-90
    • 4.2.6 Lutetium-177
    • 4.2.7 Radium-223
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Contract Manufacturing
    • 4.3.2 Quality Assurance
    • 4.3.3 Regulatory Support
    • 4.3.4 Logistics and Supply Chain Management
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cyclotron
    • 4.4.2 Nuclear Reactor
    • 4.4.3 Generator
    • 4.4.4 Linear Accelerator
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiology
    • 4.5.3 Neurology
    • 4.5.4 Endocrinology
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Liquid
    • 4.6.2 Solid
    • 4.6.3 Gas
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Diagnostic Centers
    • 4.7.3 Academic and Research Institutes
    • 4.7.4 Pharmaceutical Companies
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Synthesis
    • 4.8.2 Purification
    • 4.8.3 Labeling
    • 4.8.4 Packaging
  • 4.9 Market Size & Forecast by Equipment (2020-2035)
    • 4.9.1 PET Scanners
    • 4.9.2 SPECT Scanners
    • 4.9.3 Gamma Cameras
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Imaging Solutions
    • 4.10.2 Therapeutic Solutions
    • 4.10.3 Radiopharmacy Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Form
      • 5.2.1.7 End User
      • 5.2.1.8 Process
      • 5.2.1.9 Equipment
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Form
      • 5.2.2.7 End User
      • 5.2.2.8 Process
      • 5.2.2.9 Equipment
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Form
      • 5.2.3.7 End User
      • 5.2.3.8 Process
      • 5.2.3.9 Equipment
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Form
      • 5.3.1.7 End User
      • 5.3.1.8 Process
      • 5.3.1.9 Equipment
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Form
      • 5.3.2.7 End User
      • 5.3.2.8 Process
      • 5.3.2.9 Equipment
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Form
      • 5.3.3.7 End User
      • 5.3.3.8 Process
      • 5.3.3.9 Equipment
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Form
      • 5.4.1.7 End User
      • 5.4.1.8 Process
      • 5.4.1.9 Equipment
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Form
      • 5.4.2.7 End User
      • 5.4.2.8 Process
      • 5.4.2.9 Equipment
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Form
      • 5.4.3.7 End User
      • 5.4.3.8 Process
      • 5.4.3.9 Equipment
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Form
      • 5.4.4.7 End User
      • 5.4.4.8 Process
      • 5.4.4.9 Equipment
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Form
      • 5.4.5.7 End User
      • 5.4.5.8 Process
      • 5.4.5.9 Equipment
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Form
      • 5.4.6.7 End User
      • 5.4.6.8 Process
      • 5.4.6.9 Equipment
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Form
      • 5.4.7.7 End User
      • 5.4.7.8 Process
      • 5.4.7.9 Equipment
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Form
      • 5.5.1.7 End User
      • 5.5.1.8 Process
      • 5.5.1.9 Equipment
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Form
      • 5.5.2.7 End User
      • 5.5.2.8 Process
      • 5.5.2.9 Equipment
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Form
      • 5.5.3.7 End User
      • 5.5.3.8 Process
      • 5.5.3.9 Equipment
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Form
      • 5.5.4.7 End User
      • 5.5.4.8 Process
      • 5.5.4.9 Equipment
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Form
      • 5.5.5.7 End User
      • 5.5.5.8 Process
      • 5.5.5.9 Equipment
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Form
      • 5.5.6.7 End User
      • 5.5.6.8 Process
      • 5.5.6.9 Equipment
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Form
      • 5.6.1.7 End User
      • 5.6.1.8 Process
      • 5.6.1.9 Equipment
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Form
      • 5.6.2.7 End User
      • 5.6.2.8 Process
      • 5.6.2.9 Equipment
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Form
      • 5.6.3.7 End User
      • 5.6.3.8 Process
      • 5.6.3.9 Equipment
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Form
      • 5.6.4.7 End User
      • 5.6.4.8 Process
      • 5.6.4.9 Equipment
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Form
      • 5.6.5.7 End User
      • 5.6.5.8 Process
      • 5.6.5.9 Equipment
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Advanced Accelerator Applications
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Blue Earth Diagnostics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 ITM Isotopen Technologien Munchen
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Cyclopharm
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 NorthStar Medical Radioisotopes
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Jubilant Radiopharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Sofie Biosciences
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Shine Medical Technologies
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Eckert & Ziegler
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Isotopia Molecular Imaging
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Curium Pharma
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Trace-Ability
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Telix Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Alpha Tau Medical
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Radiomedix
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us